Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021
Cash and cash equivalents	2,455,800)	2,962,600)	3,118,100)	2,506,400)	1,995,800)	3,090,200)	2,488,200)	2,011,800)	1,920,700)	2,602,000)	2,730,000)	2,152,300)	1,937,200)	3,916,300)	3,105,900)	3,491,300)	3,395,100)	3,345,700)	2,885,600)	3,432,400)	2,072,200)	1,437,900)
Marketable securities	5,538,800)	5,791,100)	5,487,100)	5,937,200)	5,473,800)	5,259,200)	6,524,300)	7,784,700)	7,888,300)	7,917,500)	8,114,800)	7,761,300)	6,990,500)	5,043,400)	4,636,400)	3,530,400)	4,171,300)	3,704,900)	2,809,100)	2,355,200)	1,838,600)	2,065,900)
Accounts receivable, net	6,565,400)	5,731,000)	5,741,100)	5,687,100)	5,610,000)	5,561,000)	6,211,900)	6,107,100)	5,717,100)	5,222,200)	5,667,300)	5,584,500)	5,121,300)	5,118,600)	5,328,700)	5,548,300)	5,161,400)	4,839,000)	6,036,500)	5,452,000)	6,998,600)	4,173,000)
Inventories	3,084,300)	3,103,600)	3,200,800)	3,254,400)	3,205,600)	3,192,400)	3,087,300)	3,018,000)	2,873,600)	2,714,900)	2,580,500)	2,562,000)	2,507,700)	2,424,700)	2,401,900)	2,412,200)	2,218,500)	1,991,500)	1,951,300)	2,053,800)	1,983,900)	2,164,700)
Prepaid expenses and other current assets	801,700)	620,900)	474,800)	595,600)	574,300)	468,900)	349,200)	412,000)	681,900)	414,900)	386,600)	574,700)	366,300)	406,200)	411,200)	446,400)	583,600)	424,900)	332,400)	482,000)	444,300)	213,600)
Current assets	18,446,000)	18,209,200)	18,021,900)	17,980,700)	16,859,500)	17,571,700)	18,660,900)	19,333,600)	19,081,600)	18,871,500)	19,479,200)	18,634,800)	16,923,000)	16,909,200)	15,884,100)	15,428,600)	15,529,900)	14,306,000)	14,014,900)	13,775,400)	13,337,600)	10,055,100)
Marketable securities	9,828,300)	9,786,000)	10,260,600)	10,285,700)	10,058,200)	9,276,300)	8,900,100)	8,490,900)	7,722,400)	6,978,800)	5,396,500)	5,778,500)	6,327,200)	6,066,600)	6,591,800)	5,968,600)	6,415,900)	7,084,000)	6,838,000)	5,631,300)	3,900,300)	3,543,700)
Property, plant, and equipment, net	5,458,900)	5,266,100)	5,120,400)	5,002,300)	4,840,700)	4,694,200)	4,599,700)	4,439,200)	4,305,900)	4,225,500)	4,146,400)	4,006,100)	3,922,600)	3,880,900)	3,763,000)	3,704,200)	3,637,700)	3,556,400)	3,482,200)	3,395,700)	3,358,500)	3,262,600)
Intangible assets, net	1,309,800)	1,286,900)	1,257,400)	1,380,900)	1,351,700)	1,167,000)	1,148,600)	1,120,100)	1,102,200)	1,058,700)	1,038,600)	1,017,200)	953,000)	928,700)	915,500)	804,100)	—)	—)	—)	—)	—)	—)
Deferred tax assets	4,381,400)	4,190,900)	4,077,200)	3,846,700)	3,572,200)	3,442,900)	3,314,100)	3,015,100)	2,880,900)	2,764,900)	2,575,400)	2,316,800)	2,138,500)	1,924,900)	1,723,700)	1,452,100)	1,352,400)	1,140,300)	876,900)	723,200)	746,600)	765,100)
Other noncurrent assets	2,306,200)	2,129,700)	1,821,200)	1,673,100)	1,536,900)	1,393,100)	1,136,000)	1,043,000)	993,800)	470,200)	444,100)	409,900)	393,200)	349,600)	336,400)	320,200)	269,900)	262,000)	222,800)	145,900)	142,900)	145,700)
Noncurrent assets	23,284,600)	22,659,600)	22,536,800)	22,188,700)	21,359,700)	19,973,500)	19,098,500)	18,108,300)	17,005,200)	15,498,100)	13,601,000)	13,528,500)	13,734,500)	13,150,700)	13,330,400)	12,249,200)	11,675,900)	12,042,700)	11,419,900)	9,896,100)	8,148,300)	7,717,100)
Total assets	41,730,600)	40,868,800)	40,558,700)	40,169,400)	38,219,200)	37,545,200)	37,759,400)	37,441,900)	36,086,800)	34,369,600)	33,080,200)	32,163,300)	30,657,500)	30,059,900)	29,214,500)	27,677,800)	27,205,800)	26,348,700)	25,434,800)	23,671,500)	21,485,900)	17,772,200)

Total assets exhibit a consistent and significant upward trajectory, growing from $17.77 billion in March 2021 to $41.73 billion by June 2026. This expansion is driven by steady increases in both current and noncurrent asset categories, with the noncurrent asset base experiencing more aggressive growth over the analyzed period.

Current Asset Trends: Current assets rose from $10.06 billion to $18.45 billion. Cash and cash equivalents showed volatility, peaking at $3.92 billion in March 2023 before stabilizing between $1.9 billion and $3.1 billion. Marketable securities within current assets increased from $2.07 billion to $5.54 billion, despite some fluctuations. Accounts receivable, net, demonstrated a general upward trend, rising from $4.17 billion to $6.57 billion, while inventories grew steadily from $2.16 billion to $3.08 billion, suggesting an increase in operational scale and product distribution.
Noncurrent Asset Growth: Noncurrent assets grew substantially from $7.72 billion to $23.28 billion. A primary driver of this growth was the expansion of noncurrent marketable securities, which nearly tripled from $3.54 billion to $9.83 billion. Property, plant, and equipment, net, increased consistently from $3.26 billion to $5.46 billion, indicating ongoing investment in physical infrastructure. Deferred tax assets showed the most dramatic relative increase, climbing from $765.1 million to $4.38 billion.
Intangible and Other Assets: Intangible assets first appeared in the records in September 2022 at $804.1 million and grew to $1.31 billion by June 2026. Other noncurrent assets also saw a marked increase, rising from $145.7 million to $2.31 billion, contributing to the overall broadening of the balance sheet.
Asset Composition Shift: The proportion of total assets held in noncurrent categories increased over time. In March 2021, noncurrent assets represented approximately 43% of total assets; by June 2026, this figure increased to approximately 56%. This shift indicates a strategic transition toward long-term investments and infrastructure rather than maintaining purely short-term liquidity.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Assets
Quarterly Data

Assets: Selected Items

Current Assets: Selected Items

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: AssetsQuarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data